PHITT Newsletter

ISSUE 4 December 2018

Welcome

Welcome to the fourth edition of the PHITT Clinical Trial newsletter.

We would like to thank all of our UK and International colleagues for working hard this year to open sites and recruit patients into the trial. We hope that 2019 will see the trial open in all of the expected countries and sites and that the trial is successful in offering treatment to as many patients as possible.

Wishing you a very Merry Christmas and a Happy New Year! *The PHITT Team, CRCTU*

Inside this issue:

Welcome	1
15 Months On	1
15 Months On –Trial Recruitment and CRF Return	2
Associated PHITT Trials	2
Version 3.0 Of The PHITT Trial Protocol	3
Version 3.0 Of The PHITT Trial Protocol cont.	4
Contact Details	

15 Months On

STOP PRESS!! Version 3.0 of The PHITT Trial Protocol is about to be issued!

The Trial has been open to recruitment now for 15 months. There are now **17 sites open** in the UK: Southampton, Leicester and Cardiff are yet to open. There are now **5 Countries** open: Republic of Ireland (1 out of 1 site open), Spain (6 out of 20 sites open), Norway (1 out of 4 sites open), Switzerland (8 out of 9 sites open) and France (2 out of 26 sites open) with more NCCs to open soon.

A total of **30 patients** has been recruited into the PHITT study so far, 24 from the UK and 6 from Spain, in all Treatment Groups (A to F) and including Trial Entry Only.

The main news is that Version 3.0 of the PHITT Trial Protocol will be issued around Christmas 2018. See Page 3 for further information. Subsequently, this also means that Patient Information Sheets, CRFs and the PHITT Trial Online Database will be updated.



t No 668596

15 Months On -

Trial Recruitment and Data Return

The Table shows the recruitment figures and the percentage CRF return rate up to 4th December 2018. Now that the PHITT Trial Online Database is open, the percentage CRF return has improved considerably. Please continue to complete Case Report Forms and Sample Forms on the PHITT Trial Online Database.

Thank you to all active sites for participating in the PHITT Trial. Please continue to publicise this clinical trial, screen potential patients and recruit them if they prove eligible.

Site Name	Country	Site Activation Date	Number of Patients Recruited	Percentage CRF Return Rate
The Great North Children's Hospital, Newcastle	UK	21-Mar-2018	1	100%
Alder Hey Children's Hospital, Liverpool	UK	08-Dec-2017	1	100%
Royal Manchester Children's Hospital	UK	20-Sep-2017	3	95%
Bristol Royal Hospital for Children	UK	29-Nov-2017	3	93%
Royal Marsden Hospital, Sutton	UK	28-Sep-2017	5	78%
Hospital Universitario Son Espases, Mallorca	Spain	18-Jul-2018	1	71%
Addenbrookes Hospital, Cambridge	UK	25-Aug-2017	3	70%
Birmingham Children's Hospital	UK	11-May-2018	2	66%
Nottingham Children's Hospital	UK	10-Jan-2018	3	65%
Hospital Universitari Vall D'Hebron, Barcelona	Spain	25-May-2018	2	54%
Hospital Universitario 12 de Octubre, Madrid	Spain	24-Apr-2018	1	45%
Leeds General Infirmary	UK	01-Feb-2018	3	43%
Hospital Universitario de Cruces, Bizkaia	Spain	29-May-2018	1	31%
Hospital Universitario Virgen del Rocio, Sevilla	Spain	02-Jul-2018	1	25%

Associated PHITT Trials

The international collaborative partners of the PHITT trial are now open to recruitment.

In the USA, the Children's Oncology Group (COG) opened the Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) on 23rd May, 2018.

In Japan, the Japan Children's Cancer Group (JCCG) opened PHITT on 1st November, 2018.

Version 3.0 of the PHITT Trial Protocol

The major changes to the new Version 3.0 of the PHITT Trial Protocol are:-

Sodium thiosulfate (**STS**) is permitted in Groups A, B and C, but it must not be used for patients in Groups D, E and F

Dexrazoxane is permitted for patients receiving doxorubicin at the discretion of the treating centre

The Rapid Central Pathology Review increased to include HB patients who are over 8 years of age and/or AFP values less than 100 and all patients with HCC.

Treatment Group Eligibility: Treatment Group Specific Exclusion Criteria added— see the protocol for further details

For Concomitant Medication, the **use of live attenuated vaccines is prohibited**

Neutropenia has been removed from the list of events that should be reported on an **Expected SAR Form**

Database web address has been updated

Group B2 patients (non-randomised arm) will now have 6 cycles of cisplatin therapy

Group C: Group C5VD patients will receive vincristine and 5-FU on Day 1 to be in line with common practice

Group D: Groups D2 and D3 have been re-named as 'Group D2 (CD/CE)' and 'Group D2 (CD/VI)' respectively

Group D induction treatment schedule now specifies the cisplatin dose as always 70mg and doxorubicin is now given on days 57 and 58 in Block A3

Group E patients should have no macroscopic disease

Group F patients include those resected with macroscopic disease

Version 3.0 Of The PHITT Trial Protocol cont.

There is now a defined allowance for flexibility in treatment and study evaluation timings to be **+/- 3 days**

Dose Modifications are given for **Pulmonary Toxicity**

Patient Assessments at Screening and During Treatment:

All patients: Blood pressure, sodium and ammonia tests have been removed and a test for magnesium has now been added

Group B: The tumour assessments time-points for Groups B1 and B2 have now been clarified

Group C – SIOPEL-3HR: Tumour assessment post-surgery time-point removed to match the treatment (Figure 6 in the PHITT Protocol)

Screening and Treatment Assessments: Country specific requirements have been added

Screening: Magnesium tests, Prothrombin time (PT) during coagulation and other serology as per local practice have been added. Also, GFR and Audiology tests have been added in line with assessment tables

Contact the PHITT Trial Team

PHITT Trial Team, Children's Cancer Trials Team (CCTT), Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

✉: **phitt@trials.bham.ac.uk** ☎: **+44 (0)121 415 1061** 🖷: **+44 (0)121 414 9520**

Team Leader (CCTT-A): Nicola Fenwick ✉: N.Fenwick@bham.ac.uk | ☎+44 (0)121 415 8782 | 🖷: +44 (0)121 414 3700

Senior Trial Coordinator: Jennifer Laidler ✉: J.Laidler@bham.ac.uk | ☎ +44 (0)121 4151061 | 🖷: +44 (0)121 414 3700.

Trial Coordinator (UK): Steve Baker ✉: S.J.Baker.1@bham.ac.uk | ☎ +44 (0)121 4151061 | 🖷: +44 (0)121 414 9520.

Trial Coordinator (NCCs): Su Lee ✉: S.W.H.Lee@bham.ac.uk | ☎ +44 (0)121 4158211 | 🖷: +44 (0)121 414 9520.

Trial Administrator: Duncan Gordon ✉: D.H.Gordon@bham.ac.uk | ☎ +44 (0)121 4158211 | 🖷: +44 (0)121 414 9520.

Data Manager: Neil Werrett ✉: N.P.Werrett@bham.ac.uk | ☎ +44 (0)121 4148395 | 🖷: +44 (0)121 414 9520.